Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure. J of Skin. 2026;10(2):s727. doi:10.25251/evafb145